Whanin Pharm (KO:016580) — Market Cap & Net Worth
Market Cap & Net Worth: Whanin Pharm (016580)
Whanin Pharm (KO:016580) has a market capitalization of $127.64 Million (₩188.35 Billion) as of September 17, 2026. Listed on the KO stock exchange, this Korea-based company holds position #18356 globally and #813 in its home market, demonstrating a -1.83% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Whanin Pharm's stock price ₩10190.00 by its total outstanding shares 18483950 (18.48 Million). Also see Whanin Pharm balance sheet assets for a full breakdown of the balance sheet.
Whanin Pharm Market Cap History: 2015 to 2026
Whanin Pharm's market capitalization history from 2015 to 2026. Data shows change from $213.16 Million to $127.64 Million (-4.71% CAGR). Also see cash flow conversion of Whanin Pharm for how efficiently the company converts equity into cash flow.
Whanin Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Whanin Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Whanin Pharm share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Whanin Pharm's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
Whanin Pharm's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $175.58 Million | $141.38 Billion | $16.40 Billion | 0.00x | 0.01x |
| 2017 | $249.93 Million | $147.95 Billion | $27.17 Billion | 0.00x | 0.01x |
| 2018 | $218.66 Million | $154.66 Billion | $21.52 Billion | 0.00x | 0.01x |
| 2019 | $179.90 Million | $159.18 Billion | $18.70 Billion | 0.00x | 0.01x |
| 2020 | $198.05 Million | $171.71 Billion | $23.39 Billion | 0.00x | 0.01x |
| 2021 | $214.75 Million | $177.78 Billion | $26.66 Billion | 0.00x | 0.01x |
| 2022 | $216.03 Million | $198.93 Billion | $23.92 Billion | 0.00x | 0.01x |
| 2023 | $188.40 Million | $230.39 Billion | $29.77 Billion | 0.00x | 0.01x |
| 2024 | $147.94 Million | $259.60 Billion | $23.38 Billion | 0.00x | 0.01x |
| 2025 | $141.80 Million | $255.21 Billion | $13.60 Billion | 0.00x | 0.01x |
Competitor Companies of 016580 by Market Capitalization
Companies near Whanin Pharm in the global market cap rankings as of September 17, 2026. Review Whanin Pharm tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Whanin Pharm by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Whanin Pharm Historical Marketcap From 2015 to 2026
Between 2015 and today, Whanin Pharm's market cap moved from $213.16 Million to $ 127.64 Million, with a yearly change of -4.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩127.64 Million | -9.98% |
| 2025 | ₩141.80 Million | -4.15% |
| 2024 | ₩147.94 Million | -21.48% |
| 2023 | ₩188.40 Million | -12.79% |
| 2022 | ₩216.03 Million | +0.60% |
| 2021 | ₩214.75 Million | +8.43% |
| 2020 | ₩198.05 Million | +10.09% |
| 2019 | ₩179.90 Million | -17.73% |
| 2018 | ₩218.66 Million | -12.51% |
| 2017 | ₩249.93 Million | +42.34% |
| 2016 | ₩175.58 Million | -17.63% |
| 2015 | ₩213.16 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Whanin Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $127.64 Million USD |
| MoneyControl | $127.64 Million USD |
| MarketWatch | $127.64 Million USD |
| marketcap.company | $127.64 Million USD |
| Reuters | $127.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Whanin Pharm
Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceutical products in South Korea. The company offers products, such as gastrointestinal, respiratory, cardiovascular, antidiabetic, antibiotic, antifungal, antihistamine, antiviral, antirheumatic, muscle relaxant, nonsteroidal anti-inflammatory, smoking cessation, erectile dysfunction, prostate disease, urinary disorder, osteoporosis, an… Read more